CTOs on the Move

NextCure

www.nextcure.com

 
NextCure is a fully integrated biotechnology company discovering and developing first-in-class immunotherapy-based biologics for cancer and other diseases. The company is focused on understanding biological pathways and leveraging our FIND-IOTM technology to discover, validate and build a proprietary pipeline. We believe identifying and targeting immune pathways will promote identification of effective targets for mediating sustained immunity leading to improved outcomes for cancer patients.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million
  • www.nextcure.com
  • 9000 Virginia Manor Road Suite 200
    Beltsville, MD USA 20705
  • Phone: 240.399.4900

Executives

Name Title Contact Details

Funding

NextCure raised $93M on 11/13/2018

Similar Companies

Scorpion Therapeutics

Scorpion Therapeutics was founded to expand the reach of precision medicine to more people with cancer.

Neuraptive Therapeutics

Neuraptive is bringing novel therapeutic technology for the acute surgical repair of injured peripheral nerves.

ALK-Abello

ALK-Abello A/S is a Denmark-based company active within the pharmaceutical industry. It is primarily engaged in the development of pharmaceutical products that target the cause of allergy. The Company is focused on allergy vaccination. Its product

The Degge Group

The Degge Group is a Arlington, VA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Neumora Therapeutics

Brain diseases collectively represent one of the greatest challenges of our generation, affecting upwards of 1.5 billion people. However, treatments for many of the most prevalent brain disorders have been dominated by a single class of drugs, such as serotonin targeting antidepressants for MDD, leaving patients with a high degree of unmet medical need given the lack of diverse treatment options and mechanisms of action. We are taking a fundamentally different approach to the way treatments for brain diseases are developed. Our pipeline is comprised of programs pursuing therapeutically relevant targets implicated in Central Nervous System (CNS) diseases, each targeting a novel mechanism of action with best-in-class pharmacology. Our work is supported by our Precision Toolbox, which integrates a suite of translational, clinical, and computational tools to generate insights that can enable precision medicine approaches. Neumora is relentless in its commitment to discovering, developing and commercializing novel therapies for the 1.5 billion people living with brain diseases.